These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16556633)

  • 21. The effects of urethritis on seminal plasma HIV-1 RNA loads in homosexual men not receiving antiretroviral therapy.
    Sadiq ST; Taylor S; Copas AJ; Bennett J; Kaye S; Drake SM; Kirk S; Pillay D; Weller IV
    Sex Transm Infect; 2005 Apr; 81(2):120-3. PubMed ID: 15800087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
    Fayet Mello A; Buclin T; Franc C; Colombo S; Cruchon S; Guignard N; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    J Antimicrob Chemother; 2011 Jul; 66(7):1573-81. PubMed ID: 21508009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.
    Marcelin AG; Tubiana R; Lambert-Niclot S; Lefebvre G; Dominguez S; Bonmarchand M; Vauthier-Brouzes D; Marguet F; Mousset-Simeon N; Peytavin G; Poirot C
    AIDS; 2008 Aug; 22(13):1677-9. PubMed ID: 18670231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Darunavir concentrations exceed the protein-corrected EC₅₀ for wild-type HIV in the semen of HIV-1-infected men.
    Taylor S; Jayasuriya AN; Berry A; Gilleran G; Dufty NE; Else L; Back DJ; Smit EJ
    AIDS; 2010 Oct; 24(16):2583-7. PubMed ID: 20736813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
    Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
    Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
    J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral drug concentrations in semen of HIV-1 infected men.
    Taylor S; Pereira AS
    Sex Transm Infect; 2001 Feb; 77(1):4-11. PubMed ID: 11158684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.
    Imaz A; Martinez-Picado J; Niubó J; Kashuba AD; Ferrer E; Ouchi D; Sykes C; Rozas N; Acerete L; Curto J; Vila A; Podzamczer D
    J Infect Dis; 2016 Nov; 214(10):1512-1519. PubMed ID: 27578849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
    Shelton MJ; Mei H; Hewitt RG; Defrancesco R
    Antimicrob Agents Chemother; 2001 Jan; 45(1):298-300. PubMed ID: 11120981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
    van der Lugt J; Autar RS; Ubolyam S; Garcia EF; Sankote J; Avihingsanon A; Chuenyam T; Cooper DA; Lange J; Phanuphak P; Wit F; Ruxrungtham K; Burger D;
    J Antimicrob Chemother; 2008 May; 61(5):1145-53. PubMed ID: 18285316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.
    Chaudry NI; Eron JJ; Naderer OJ; Pereira AS; Wire MB; Fiscus SA; Kashuba AD
    Clin Infect Dis; 2002 Sep; 35(6):760-2. PubMed ID: 12203175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
    AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
    Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
    Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The male genital tract: A host for HIV].
    Le Tortorec A; Dejucq-Rainsford N
    Gynecol Obstet Fertil; 2007 Dec; 35(12):1245-50. PubMed ID: 18035579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.